COMBINATION THERAPY USING ANTIBODIES AGAINST CLAUDIN 18.2 FOR CANCER TREATMENT Russian patent published in 2023 - IPC A61K39/395 A61K31/7068 A61K31/663 A61K38/20 A61K31/282 A61K33/243 A61P35/00 

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine; it can be used for the treatment of precancerous lesion of the pancreas, characterized by pancreas cells expressing claudin 18 splicing variant 2 (hereinafter – CLDN18.2), in a patient. For this purpose, the patient is administered with (i) an antibody having a capability of binding to CLDN18.2 and (ii) an agent stabilizing or increasing CLDN18.2 expression. The antibody binds to CLDN18.2 and provides destruction of cells expressing CLDN18.2, wherein the antibody contains an antibody heavy chain containing an amino acid sequence represented with SEQ ID NO: 32 and an antibody light chain containing an amino acid sequence represented with SEQ ID NO: 39. The agent stabilizing or increasing CLDN18.2 expression is a nucleoside analogue selected from a group consisting of gemcitabine and its composite ester or salt. An option of the specified method, including additional administration to the patient of bisphosphonate, is also disclosed.

EFFECT: group of inventions provides effective treatment of precancerous lesion of the pancreas.

11 cl, 45 dwg, 21 tbl, 10 ex